GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aratana Therapeutics Inc (NAS:PETX) » Definitions » Shares Outstanding (Basic Average)

Aratana Therapeutics (Aratana Therapeutics) Shares Outstanding (Basic Average) : 48.28 Mil (As of Mar. 2019)


View and export this data going back to 2013. Start your Free Trial

What is Aratana Therapeutics Shares Outstanding (Basic Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Aratana Therapeutics's average basic shares outstanding for the quarter that ended in Mar. 2019 was 48.28 Mil.


Aratana Therapeutics Shares Outstanding (Basic Average) Historical Data

The historical data trend for Aratana Therapeutics's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aratana Therapeutics Shares Outstanding (Basic Average) Chart

Aratana Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial 29.77 34.36 35.27 40.49 46.61

Aratana Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.79 46.26 47.31 48.04 48.28

Aratana Therapeutics Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Aratana Therapeutics  (NAS:PETX) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Aratana Therapeutics Shares Outstanding (Basic Average) Related Terms

Thank you for viewing the detailed overview of Aratana Therapeutics's Shares Outstanding (Basic Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aratana Therapeutics (Aratana Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS, USA, 66211
Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics. The main product candidates in development comprise small-molecule pharmaceuticals directed at treating osteoarthritis pain, inflammation, appetite stimulation, and post-operative pain. The firm's strategy consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.
Executives
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Vort John Vander director C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lowell W Robinson director 470 WEST END AVENUE, NEW YORK NY 10024
Wendy L Yarno director
David L Brinkley director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Craig A. Barbarosh director 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Hockaday Irvine O Jr director SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191
Craig A Tooman director, officer: President and CEO
Peter Steven St director, officer: PRESIDENT AND CEO MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Jay Lichter director C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211